4
Changes in Ownership
Atara Biotherapeutics, Inc. Filed Acc 0001209191-19-008526
EVP, R&D & Chief Scientific Of sold 12,375 shares at an average $38.62 ($477,922)
- EVP, R&D & Chief Scientific Of gave up 1,512 shares (to pay taxes)
- EVP, R&D & Chief Scientific Of acquired 15,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Haqq Christopher EVP, R&D & Chief Scientific Of | 2019-02-06 | Sale | −2,677 | $38.04 | $101,833 | 282,903 | D |
| Haqq Christopher EVP, R&D & Chief Scientific Of | 2019-02-06 | Sale | −9,698 | $38.78 | $376,088 | 273,205 | D |
| Haqq Christopher EVP, R&D & Chief Scientific Of | 2019-02-06 | Shares withheld for taxes | −1,512 | $38.47 | $58,167 | 271,693 | D |
| Haqq Christopher EVP, R&D & Chief Scientific Of | 2019-02-06 | Grant or award | +15,000 | 286,693 | D | ||
| Derivatives | |||||||
| Haqq Christopher EVP, R&D & Chief Scientific Of | 2019-02-06 | Grant or award · Employee Stock Option (Right to Buy) | +30,000 | 30,000 | D | ||
| Open-market sales · 12,375 sh · avg $38.62 · $477,922 | |||||||
Loading xslF345X03/doc4.xml…